INTRODUCTION
============

Primary Sjogren's syndrome (pSS) is an autoimmune disease that affects the exocrine glands, leading to the development of keratoconjunctivitis sicca and xerostomia \[[@b1-kjim-2015-219]\]. The prevalence of extraglandular manifestations (EGMs) including cytopenia, arthritis, neuropathy, interstitial lung disease, and renal disease varies from 40% to 50% \[[@b2-kjim-2015-219]\] to 86% \[[@b3-kjim-2015-219]\]. Peripheral neuropathy is a well-known EGM in patients with pSS \[[@b4-kjim-2015-219]\] and presents as a mild sensory, mixed, trigeminal, or latent motor neuropathy and mononeuritis multiplex \[[@b5-kjim-2015-219]\]. Peripheral neuropathy has been reported in approximately 20% of patients with pSS \[[@b4-kjim-2015-219]\]. The autonomic nervous system (ANS) is part of the peripheral nervous system (PNS) and is responsible for maintaining homeostasis in the body. Several studies have described ANS dysfunction in pSS \[[@b4-kjim-2015-219],[@b6-kjim-2015-219]-[@b8-kjim-2015-219]\].

Autonomic dysfunction may affect both glandular manifestations and EGMs in patients with pSS. Since the degree of exocrine gland destruction and exocrine function are poorly correlated, a possible mechanism involving disturbed neural stimulation of the residual glands regulates secretion has been proposed \[[@b9-kjim-2015-219]\]. In addition, some studies have demonstrated that autonomic dysfunction correlates with pSS-associated symptoms and disease activity \[[@b7-kjim-2015-219],[@b10-kjim-2015-219]\].

The ANS can be assessed using various methods. Short-term heart rate variability (HRV) is the most commonly used, fastest, and non-invasive method for objective measurement of autonomic function. It analyzes the variability of time interval between R waves \[[@b11-kjim-2015-219]\]. Several studies have demonstrated an association between autonomic dysfunction and pSS using questionnaires on autonomic symptoms \[[@b8-kjim-2015-219],[@b10-kjim-2015-219]\] or tests for dynamic orthostasis \[[@b4-kjim-2015-219],[@b6-kjim-2015-219],[@b7-kjim-2015-219]\]. A comprehensive analysis encompassing physiological variables, including assessment of autonomic dysfunction using HRV in pSS patients, has not been fully investigated.

In this study, we evaluated the autonomic dysfunction in a large cohort of Korean patients with clinically well-characterized pSS compared to healthy controls by using HRV. Then, we determined the prevalence of autonomic dysfunction in patients with pSS. In addition, we explored the relationships among autonomic dysfunction and disease activity, patient-reported outcome measures, as well as other potentially relevant clinical and laboratory variables.

METHODS
=======

Study population
----------------

All pSS patients in this study were participants of the Korean Initiative of primary Sjogren's Syndrome (KISS). KISS was formed in 2013 with the aim of establishing a nationwide prospective cohort with the overall clinical data and samples of pSS patients and developing diagnostic and treatment tools for pSS. Informed consent was obtained from all patients according to the principles of the Declaration of Helsinki. This study was approved by the Institutional Review Board of Seoul St. Mary's Hospital (KC13ONMI0646). All data were collected and managed with the Clinical Research and Trial Management System (iCReaT; Korea National Institutes of Health, Korea Centers for Disease Control and Prevention).

The recruitment began in the Seoul St. Mary's Hospital, a tertiary care university hospital and referral center in Seoul, Korea, in October 2013. By April 2015, the database included 175 pSS patients from the Seoul St. Mary's hospital, who fulfilled the 2002 American-European Consensus group classification criteria \[[@b12-kjim-2015-219]\] and/or the 2012 American College of Rheumatology criteria \[[@b13-kjim-2015-219]\]. The exclusion criteria were a history of radiation to the head and neck areas, chronic hepatitis C or human immunodeficiency virus infections, previous lymphoproliferative disease, sarcoidosis, graft-versus-host disease, amyloidosis, immunoglobulin G4-related disease, and associated systemic autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, primary biliary cirrhosis, vasculitis, autoimmune hepatitis, and systemic sclerosis. One male patient, three with diabetes mellitus four with hypertension and 13 with fibromyalgia were not included in this study, because gender, diabetes mellitus, hypertension, and fibromyalgia can affect the HRV test results \[[@b14-kjim-2015-219],[@b15-kjim-2015-219]\]. [Fig. 1](#f1-kjim-2015-219){ref-type="fig"} shows the number of participants involved in this study from assessment for eligibility. Finally, 154 patients from the KISS cohort were included in this study. Each pSS patient was age-matched to a healthy control who had visited our hospital for a regular check-up. None of the patients had concomitant conditions such as neuropsychiatric disease, amyloidosis, renal failure, diabetes mellitus, hypertension, cardiac arrhythmia, and hypo/hyperthyroidism.

Assessment of autonomic function
--------------------------------

Participants were asked to refrain from eating and drinking caffeinated beverages for at least 8 hours before the examination. A standardized 5-minute supine resting study, including a spectral analysis of the heart rate, was conducted. Data collection and HRV analysis were performed using the SA-3000P (Medicore Co., Seongnam, Korea). In all pSS patients and controls, the following HRV parameters were analyzed \[[@b11-kjim-2015-219]\].

\(1\) Time domain

1.  Standard deviation of normal-to-normal RR intervals (SDNN, ms)

2.  Root mean square of successive differences in normal to normal intervals (RMSSD, ms)

\(2\) Frequency domain

1.  Total power (TP) component (0 to 0.4 Hz)

2.  Low frequency (LF) component (0.04 to 0.15 Hz)

3.  High frequency (HF) component (0.15 to 0.4 Hz)

4.  LF/HF ratio

5.  LF or HF in normalized units (n.u.): LF or HF/(TP -- very LF) × 100

According to the low TP, the raw HF and LF could be relatively low. Normalized LF and HF components would therefore better demonstrate the behavior of the sympathetic and parasympathetic branches of the ANS. Autonomic dysfunction was defined as a SDNN \< 30 ms in patients \< 50 years old and SDNN \< 20 ms in patients ≥ 50 years old, based on the large Korean short-term HRV study and age-related influences \[[@b16-kjim-2015-219],[@b17-kjim-2015-219]\].

The 75th percentile of the LF/HF ratio in healthy controls was 1.6 and was considered as an upper reference limit. In this study, the higher LF/HF ratio indicated relatively decreased parasympathetic activity.

Assessment of other clinical features of pSS
--------------------------------------------

The following data were collected for all KISS participants: European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI; range, 0 to 123) \[[@b18-kjim-2015-219]\], EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI; range, 0 to 10) \[[@b19-kjim-2015-219]\], Patient's global assessment, Physician's global assessment, unstimulated salivary flow rate, xerostomia inventory (range, 11 to 55) \[[@b20-kjim-2015-219]\], ocular surface disease index (OSDI; range, 0 to 100) \[[@b21-kjim-2015-219]\], ocular stain score (OSS), tear film break-up time (TBUT), and meibomian gland dysfunction grade.

Statistical analysis
--------------------

All data were analyzed using SAS software version 9.3 (SAS Institute, Cary, NC, USA). The Shapiro-Wilk test was used to test for departures from normality of distribution for continuous outcome variables. Variables were usually skewed; continuous variables are therefore expressed as median (interquartile range \[IQR\]), while categorical data are expressed in absolute and percentage values (%). When comparing groups, the Mann-Whitney *U* test was applied to two groups of continuous variables, and the chi-square test was performed for categorical variables. Statistical significance was set at *p* \< 0.05.

RESULTS
=======

Baseline characteristics
------------------------

The participants consisted of 154 women with a median age of 55 years (IQR, 47 to 60) and a median pSS duration of 2.1 years (IQR, 0.5 to 4.8). All participants fulfilled the 2002 classification criteria \[[@b12-kjim-2015-219]\] (n = 151, 98.1%) and/or the 2012 classification criteria \[[@b13-kjim-2015-219]\] (n = 114, 74.0%). All participants were non-smokers, and 66.2% (n = 102) were postmenopausal.

Current EGMs were observed in 73.6% of the participants. Autonomic dysfunction was observed with the HRV test in 35.7% of the participants. The autoimmune antibody profiles revealed anti-Ro/SSA (anti-Ro/Sjogren's syndrome A antibody) in 90.3% and anti-La/SSB (anti-La/Sjogren's syndrome B antibody) in 46.8% of the participants. The median ESSDAI and ESSPRI scores were 3 (IQR, 0 to 6) and 5 (IQR, 4 to 6), respectively.

Autonomic dysfunction in patients with pSS
------------------------------------------

The overall autonomic influence (SDNN and RMSSD) was lower in pSS patients ≥ 50 years old than in those \< 50 years old, whereas the parasympathetic and sympathetic activity (LF, \[n.u.\], HF, \[n.u.\], and LF/HF ratio) was not different according to age ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We compared the HRV indices between age- and sex-matched healthy controls and patients with pSS. SDNN and TP, the parameters related to the overall autonomic activity, were significantly lower in patients with PSS than in controls during the 5-minute supine resting study ([Table 1](#t1-kjim-2015-219){ref-type="table"}). The normalized HF component was significantly low in patients with pSS compared to healthy controls (*p* = 0.027), whereas the normalized LF component was not significantly different between patients with pSS and healthy controls. The LF/HF ratio was higher in patients with pSS than in healthy controls (1.3 and 0.9, respectively, *p* = 0.042). Since the HF component is mainly modulated by the parasympathetic system, and the LF component is regulated by both the sympathetic and parasympathetic drive, a reduced normalized HF component and not significantly elevated normalized LF component indicated a relative impairment of the parasympathetic system. The higher LF/HF ratio reflects relatively dominant sympathetic activity. In the circumstance with a decreased normalized HF component and not elevated normalized LF component, the higher ratio indicated relatively decreased parasympathetic activity.

Comparison of clinical manifestations between pSS patients with and without autonomic dysfunction
-------------------------------------------------------------------------------------------------

Age, disease duration, and body mass index were not associated with autonomic dysfunction. Raynaud's phenomenon was observed in 29.4% of patients with autonomic dysfunction, whereas it was observed in 14.4% of patients without autonomic dysfunction (*p* = 0.048). EGMs defined as the presence of disease activity in any ESSDAI domain except the glandular domain alone were not different between patients with and without autonomic dysfunction. A comparison of the glandular symptom severity indices assessed using the OSDI and xerostomia inventory, ocular signs assessed using the OSS, meibomian gland dysfunction and TBUT, and unstimulated salivary flow rate for 15 minutes in patients with and without autonomic dysfunction revealed no significant differences.

The overall ESSDAI and ESSPRI scores were not different according to the presence of autonomic dysfunction. However, the ESSPRI fatigue score was higher in patients with autonomic dysfunction (6 \[5 to 7\] vs. 5 \[3 to 7\]) than in those without autonomic dysfunction (*p* = 0.024) ([Table 2](#t2-kjim-2015-219){ref-type="table"}).

Among patients with pSS, 42% (n = 64) showed decreased parasympathetic activity. The decreased parasympathetic activity was not associated with ocular and oral signs such as the OSS, TBUT, presence of meibomian gland dysfunction, and unstimulated and stimulated salivary flow rate ([Table 3](#t3-kjim-2015-219){ref-type="table"}). The ESSPRI pain score was higher in patients with decreased parasympathetic activity than in those without. None of the HRV parameters correlated with disease specific measurements or laboratory features.

DISCUSSION
==========

In the present study, we found an overall decrease and imbalance in autonomic activity in patients with pSS compared to healthy controls. This study demonstrated that autonomic dysfunction in pSS was associated with overall fatigue, whereas autonomic dysfunction was poorly associated with exocrine manifestations and EGMs of pSS.

Although the association of autonomic dysfunction with pSS has been debated in the literature \[[@b4-kjim-2015-219],[@b6-kjim-2015-219],[@b7-kjim-2015-219],[@b10-kjim-2015-219],[@b22-kjim-2015-219],[@b23-kjim-2015-219]\], majority of the studies have endorsed a positive association between them. Our results also revealed that many pSS patients have restricted HRV but normal heart rate and blood pressure in the resting state. This discrepancy in the results could be explained by methodological variations in the tests used, such as the conventional cardiovascular reflex test, baroreflex sensitivity test, and HRV test. Because of better sensitivity and reproducibility compared to reflex tests \[[@b24-kjim-2015-219]\], HRV analysis is widely used in ANS investigations. Reduced HRV is a powerful and independent predictor of a cardiac event in the general population \[[@b25-kjim-2015-219]-[@b27-kjim-2015-219]\]. Furthermore, recent studies demonstrated that the cardiovascular risk burden in pSS patients is increased compared to that in the general population \[[@b28-kjim-2015-219],[@b29-kjim-2015-219]\]. A long-term follow-up study is needed to explore the relationship between autonomic dysfunction and cardiovascular disease.

Exocrine secretion is controlled by the ANS; it consists of liquid secretion, which is mainly parasympathetic, and protein secretion, which is mainly sympathetically modulated \[[@b30-kjim-2015-219]\]. Antibodies to muscarinic acetylcholine receptors have been demonstrated in patients with pSS; this suggests an association between autonomic and exocrine dysfunctions in pSS \[[@b31-kjim-2015-219],[@b32-kjim-2015-219]\]. Imrich et al. \[[@b33-kjim-2015-219]\] demonstrated that decreased glandular parasympathetic activity was associated with hyposalivation. They also described that hemodynamic parameters evaluated using the tilt table test are not different between patients with pSS and controls. Although we could not demonstrate an association between autonomic dysfunction and tear/salivary secretion, we proposed that decreased parasympathetic activity contributed to autonomic imbalance in patients with pSS. Raynaud's phenomenon, which is caused by sympathetic impairment in the regulation of peripheral blood flow, was seen more frequently in pSS patients with autonomic dysfunction than in those without. Decrease in overall autonomic activity is postulated as the cause. Some studies also found relative impairment of the sympathetic nervous system \[[@b7-kjim-2015-219],[@b34-kjim-2015-219]\].

In this study, autonomic dysfunction was associated with the ESSPRI fatigue score in patients with pSS. These findings are consistent with those of previous studies, which reported that orthostatic dysfunction \[[@b7-kjim-2015-219]\] and higher autonomic dysfunction symptom profile scores \[[@b8-kjim-2015-219],[@b10-kjim-2015-219]\] are prevalent in patients with pSS and are correlated with fatigue. Fatigue is a common, disabling extraglandular symptom of pSS, and the prevalence of clinically significant fatigue is 57% to 74% \[[@b35-kjim-2015-219]\]. Fatigue is a self-reported symptom and is involved with multiple physiological and psychological interactions. A negative correlation between the noradrenalin level and general fatigue has been observed in patients with pSS \[[@b36-kjim-2015-219]\], suggesting that autonomic dysfunction could be one of the physiological factors associated with fatigue.

Interestingly, decreased parasympathetic activity was associated with higher ESSPRI pain scores. Patients with fibromyalgia have significantly lower HRV and parasympathetic activity compared to healthy controls \[[@b37-kjim-2015-219]\]. Although pSS patients with fibromyalgia were excluded in this study, we supposed that patients with pSS were vulnerable to pain when they presented with decreased parasympathetic activity. As the median duration of pSS in the KISS cohort is relatively short, a follow-up study is needed to ascertain that autonomic dysfunction including a decreased parasympathetic activity predicts development of fibromyalgia.

Although autonomic dysfunction is prevalent in patients with pSS, there is no consensus regarding an appropriate method for assessing it. Ng et al. \[[@b7-kjim-2015-219]\] reported that the total Composite Autonomic Symptom scale score was independently correlated with the ESSPRI, ESSDAI, Hospital Anxiety and Depression Scale, and mental fatigue score. As the PNS domain in the ESSDAI does not include autonomic symptoms, no statistical association between autonomic dysfunction and the PNS domain in the ESSDAI was identified in this study. Assessment of the ANS using the 5-minute HRV test could be considered as an ancillary method for assessing disease activity in patients with pSS.

A potential limitation of the current study is that we did not evaluate the symptoms of autonomic dysfunction. Detailed autonomic symptoms such as orthostatic intolerance, and vasomotor, secretomotor, and gastrointestinal dysfunction are generally assessed using the Composite Autonomic Symptom Scale or autonomic symptom profile. However, this study assessed autonomic dysfunction using HRV in a relatively large, well-defined pSS cohort. In contrast to the self-reported autonomic symptom questionnaire, the short-term HRV test is relatively insusceptible to the respondents. The short-term HRV test is a non-invasive method to objectively evaluate autonomic dysfunction and has been shown to correlate well with the 24-hour HRV test \[[@b17-kjim-2015-219],[@b38-kjim-2015-219]\]. Another potential limitation is that patients with autonomic dysfunction could be misclassified. We divided pSS patients into two groups with and without autonomic dysfunction by age dependent SDNN value. This was used because there are no cut-offs available for clinically relevant autonomic dysfunction. This cut-off value was defined according to previous large population based studies \[[@b16-kjim-2015-219],[@b17-kjim-2015-219]\] and was validated in our healthy control ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

In conclusion, autonomic dysfunction is relatively prevalent in patients with pSS and is associated with fatigue. Parasympathetic activity is relatively decreased in these patients; however, it is not associated with exocrine function.

KEY MESSAGE
===========

1\. Autonomic dysfunction is prevalent in patients with primary Sjogren's syndrome and is assessed using the 5-minute supine resting heart rate variability test.

2\. Autonomic dysfunction is associated with the severity of fatigue in patients with primary Sjogren's syndrome. However, no association was detected between autonomic dysfunction and exocrine function in these patients.
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###### 

Comparison of heart rate variability profile according to age stratified by healthy control and pSS patients

![Enrollment, and patients selection \[12,13\]. AECG, American-European Consensus Group; ACR, American College of Rheumatology; IgG4, immunoglobulin G4.](kjim-2015-219f1){#f1-kjim-2015-219}

###### 

Heart rate variability parameters of patients with primary Sjogren's syndrome and controls

  HRV domain                 Patients with pSS (n = 154)   Controls (n = 154)       *p* value
  -------------------------- ----------------------------- ------------------------ -----------
  Age, yr                    55 (47--60)                   55 (47--60)              0.623
  Body mass index, kg/m^2^   22.5 (20.7--24.2)             22.0 (20.4--24.2)        0.262
  Heart rate, /min           68 (63--74)                   71 (64--77)              0.004
  SDNN, ms                   26.3 (21.6--34.2)             35.0 (25.9--57.3)        \< 0.001
  RMSSD, ms                  18.8 (14.0--30.0)             21.3 (14.2--31.1)        0.345
  Total power, ms^2^         463.4 (298.2--793.2)          588.1 (288.4--1,259.8)   0.042
  Low frequency, ms^2^       104.2 (56.2--181.5)           119.9 (54.3--312.4)      0.035
  Low frequency, n.u.        55.3 (55.3--68.8)             48.3 (38.0--60.6)        0.096
  High frequency, ms^2^      77.6 (39.8--162.7)            123.5 (55.1--326.0)      0.001
  High frequency, n.u.       43.2 (29.6--64.0)             51.5 (38.8--61.1)        0.027
  LF/HF ratio                1.3 (0.5--2.2)                0.9 (0.6--1.6)           0.042

Values are presented as median (interquartile range).

HRV, heart rate variability; pSS, primary Sjogren's syndrome; SDNN, standard deviation of normal-to-normal RR intervals; RMSSD, root mean square of successive difference in normal to normal intervals; n.u., normalized unit; LF, low frequency; HF, high frequency.

###### 

Comparison of clinical manifestations between patients with and without autonomic dysfunction in primary Sjogren's syndrome

  Characteristic                                     Total            Autonomic dysfunction (n = 55)   No autonomic dysfunction (n = 99)   *p* value
  -------------------------------------------------- ---------------- -------------------------------- ----------------------------------- -----------
  Age, yr                                            55 (47--60)      52 (46--59)                      55 (46--59)                         0.355
  Disease duration, yr                               2.1 (0.5--4.8)   1.2 (0.2--4.0)                   2.3 (0.6--5.8)                      0.122
  Body mass index, kg/m^2^                           23 (21--24)      22 (21--25)                      23 (21--24)                         0.677
  Menopause                                          102 (66.2)       34 (61.8)                        68 (68.7)                           0.477
  Current EGMs                                       109/148 (73.6)   38/51 (74.5)                     71/97 (73.2)                        \> 0.999
  Raynaud's phenomenon                               29/148 (19.6)    15/51 (29.4)                     14/97 (14.4)                        0.048
  Serologic profile                                                                                                                        
   Anti-Ro/SSA positive                              139 (90.3)       50 (90.9)                        89 (89.9)                           \> 0.999
   Anti-La/SSB positive                              72 (46.8)        27 (49.1)                        45 (45.5)                           0.737
  Glandular manifestations                                                                                                                 
   OSDI                                              38 (18--53)      40 (25--60)                      34 (16--53)                         0.210
   OSS                                               4 (2--6)         4 (2--6)                         4 (2--6)                            0.299
   Xerostomia inventory                              37 (30--43)      37 (31--42)                      36 (30--44)                         0.870
   Unstimulated salivary flow rate ≤ 1.5 mL/15 min   125/151 (82.8)   48/54 (88.9)                     77/97 (79.4)                        0.179
  Outcome measures                                                                                                                         
   ESSDAI                                            3 (0--6)         3 (0--6)                         3 (0--6)                            0.747
   ESSPRI                                            5 (4--7)         5 (5--6)                         5 (4--7)                            0.110
    Pain                                             3 (0--5)         3 (0--5)                         3 (0--5)                            0.777
    Fatigue                                          5 (5--7)         6 (5--7)                         5 (3--7)                            0.024
    Dryness                                          7 (5--9)         8 (6--9)                         7 (5--9)                            0.373
  Medications                                                                                                                              
   Hydroxychloroquine                                105 (68.2)       39 (70.9)                        66 (66.7)                           0.718
   Glucocorticoids                                   52 (33.8)        20 (36.4)                        32 (32.3)                           0.722
   Pilocarpine                                       124 (80.5)       45 (81.8)                        79 (79.8)                           0.834

Values are presented as median (interquartile range) or number (%).

EGM, extraglandular manifestation; SSA, Sjogren's syndrome A; SSB, Sjogren's syndrome B; OSDI, ocular surface disease index; OSS, ocular stain score; ESSDAI, European League Against Rheumatism (EULAR) Sjogren's syndrome disease activity index; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index.

###### 

Comparison of clinical manifestations between patients with and without decreased parasympathetic activity in primary Sjogren's syndrome

  Characteristic                                Decreased parasympathetic activity (n = 64)   Not decreased parasympathetic activity (n = 90)   *p* value
  --------------------------------------------- --------------------------------------------- ------------------------------------------------- -----------
  Ocular signs                                                                                                                                  
   Ocular stain score                           4 (2--6)                                      4 (2--6)                                          0.188
   Tear break-up time, sec                      3 (2--5)                                      3 (2--5)                                          0.685
   MGD                                          49/78 (62.8)                                  41/58 (70.7)                                      0.365
  Oral signs                                                                                                                                    
   Unstimulated salivary flow rate, mL/15 min   0.3 (0--0.8)                                  0.3 (0--1.0)                                      0.315
   Stimulated salivary flow rate, mL/15 min     6 (3--12)                                     9 (3--18)                                         0.1
  ESSPRI                                        5 (5--7)                                      5 (4--6)                                          0.363
   Pain                                         4 (1--6)                                      3 (0--5)                                          0.031
   Fatigue                                      5 (4--7)                                      5 (5--7)                                          0.921
   Dryness                                      8 (5--9)                                      7 (5--9)                                          0.872

Values are presented as median (interquartile range) or number (%).

MGD, meibomian gland dysfunction; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index.
